CCM
AGTC

Cadence Capital Management’s Applied Genetic Technologies Corporation AGTC Stock Holding History

Cadence Capital Management’s Portfolio AGTC Stock Details AGTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-45,950
Closed -$449K – 706
2016
Q3 		$449K Sell
45,950
-318
-0.7% -$4.29K 0.03% 503
2016
Q2 		$654K Buy
+46,268
New +$722K 0.05% 399

Other funds holding AGTC

IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cadence Capital Management's AGTC Position: Q4 2016 in Review

Cadence Capital Management sold out of Applied Genetic Technologies Corporation (AGTC) in Q4 2016, closing a stake of 45,950 shares — an estimated $449K sold.

Cadence Capital Management first reported a position in AGTC in Q2 2016 and held it in 2 quarters. The position peaked at $654K in Q2 2016. 90 funds tracked by Wall St. Rank hold AGTC as of Q4 2016.

  • Cadence Capital Management reported no remaining Applied Genetic Technologies Corporation position as of Q4 2016 after selling out during the quarter.
  • Cadence Capital Management sold 45,950 Applied Genetic Technologies Corporation shares in Q4 2016, an estimated $449K.
  • Cadence Capital Management first reported a position in Applied Genetic Technologies Corporation in Q2 2016 and held it in 2 quarters.
  • Cadence Capital Management's Applied Genetic Technologies Corporation position peaked at $654K in Q2 2016.
  • 90 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q4 2016.

Based on Cadence Capital Management's 13F filing for Q4 2016, filed 1 Feb 2017.